Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]

Authors Shiferaw D, Faruqi S

Received 25 September 2019

Accepted for publication 25 September 2019

Published 11 October 2019 Volume 2019:15 Pages 1207—1208

DOI https://doi.org/10.2147/TCRM.S232419


Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.

Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.

On page 1029, the first sentence of the introduction section reads as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately ct 380,000 people worldwide.1” This should read as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately 80,000 people worldwide.1

Read the original article


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]